CSPC Pharma Signs Major Deal with AstraZeneca

CSPC Pharmaceutical Group (HK:1093) has released an update.

CSPC Pharmaceutical Group Limited has announced a lucrative exclusive licensing agreement with AstraZeneca to develop and market their novel Lipoprotein(a) inhibitor compound, YS2302018. The deal includes an initial $100 million payment to CSPC, with the potential for up to $370 million in development milestones and up to $1.55 billion in sales milestones, plus sales royalties. The AI-developed compound shows promise in pre-clinical studies for reducing cardiovascular risk by targeting and inhibiting Lp(a) formation.

For further insights into HK:1093 stock, check out TipRanks’ Stock Analysis page.